Cutaneous Squamous Cell Carcinoma Market Size to Reach USD 4.01 Billion by 2035 on Adjuvant Immunotherapy Growth

According to DataM Intelligence, the global cutaneous squamous cell carcinoma market is valued at USD 2.00 billion in 2025 and is projected to reach USD 4.01 billion by 2035, growing at a CAGR of 7.2% across the 2026-2035 forecast period. This places the cSCC treatment market on a steady doubling trajectory over the coming decade, reflecting both the scale of the underlying disease burden and the arrival of higher-value systemic treatment options within an otherwise procedure-driven market. The market's growth story is less about a sudden change in how often cSCC occurs and more about how it is being treated.
A major turning point came with the approval of adjuvant cemiplimab, which extended immunotherapy use beyond unresectable or metastatic disease into patients treated after surgery and radiation who face a high risk of recurrence. Alongside this, earlier-stage disease is being explored as a target for intralesional immunotherapy, while transplant recipients and other immunosuppressed patients represent a distinct and still underserved segment of the cSCC market. Surgery and Mohs micrographic surgery continue to anchor the market by volume, even as immunotherapy expands its share of overall market value.
Get More About This Market Research Report: https://www.datamintelligence.com/research-report/cutaneous-squamous-cell-carcinoma-market?akash

Recent Developments
• CONTRAC-2 (July 2026): A Phase II study evaluating cemiplimab in kidney-transplant recipients with advanced cSCC was posted to ClinicalTrials.gov, using standardized immunosuppression and allowing cetuximab as salvage therapy.
• NCI Amivantamab Trial Update (July 2026): The NCI-sponsored Phase II trial comparing subcutaneous amivantamab with cetuximab in immunocompromised patients with recurrent, inoperable, or metastatic cSCC was updated to recruiting status.
• Regeneron Intralesional Cemiplimab Study (April 2026): Regeneron's Phase III trial comparing intralesional cemiplimab with primary surgery in early-stage cSCC remained in recruitment, with a planned enrollment of 369 participants.
• KEYNOTE-630 (March 2026): Merck's adjuvant pembrolizumab trial in high-risk cSCC was updated as completed on ClinicalTrials.gov, following its earlier discontinuation for futility.
• Regeneron Libtayo Milestone (January 2026): Regeneron reported that Libtayo (cemiplimab) had secured both U.S. and European approval as the first immunotherapy for high-risk adjuvant cSCC, alongside global Libtayo sales of USD 1.45 billion across all indications in 2025.

Key Growth Drivers in the Cutaneous Squamous Cell Carcinoma Market
• Adjuvant cemiplimab is reshaping the market - expansion into high-risk resected cSCC is creating a major new immunotherapy segment.
• Immunotherapy is the fastest-growing treatment segment, driven by cemiplimab and pembrolizumab.
• Immunotherapy is moving earlier in the treatment pathway - intralesional cemiplimab is being tested against surgery for early-stage cSCC.
• Surgery and Mohs remain dominant because most cSCC is localized and surgically curable.
• Advanced cSCC is becoming a high-value chronic oncology market, with prolonged PD-1 treatment increasing revenue per patient.
• Immunosuppressed and transplant patients are a major unmet-need opportunity, driving development of checkpoint, EGFR-targeted and oncolytic therapies.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for Quick Response): https://www.datamintelligence.com/download-sample/cutaneous-squamous-cell-carcinoma-market?akash

Market Segmentation
By Treatment Type
• Surgery & Mohs Surgery
• Immunotherapy
• Radiation Therapy
• Systemic Targeted/Cytotoxic Therapy
• Other Local Treatments
Surgery and Mohs surgery lead the cSCC treatment market with an estimated 43.8% revenue share, reflecting the large localized-disease population, while immunotherapy holds about 26.7% and is expected to grow fastest as the adjuvant and advanced-disease patient base expands.
By Disease Setting
• Localized cSCC
• High-Risk Resected cSCC
• Locally Advanced cSCC
• Metastatic cSCC
Localized cSCC generates the largest share of market revenue, at an estimated 58.5%, due to high case volumes, while high-risk resected disease (22.8%) is becoming commercially more significant following the approval of adjuvant cemiplimab.
By Diagnosis
• Biopsy & Histopathology
• CT
• MRI
• Other Imaging
Biopsy and histopathology remain central to confirming cSCC before treatment selection, with imaging methods such as CT and MRI supporting staging and treatment planning in more advanced cases.
By End User
• Hospitals & Cancer Centers
• Dermatology/Specialty Clinics
• Ambulatory Surgical Centers
• Others
Hospitals and cancer centers are estimated to hold the largest end-user share, at 44.5%, driven by radiation treatment and intravenous immunotherapy, while dermatology and specialty skin-cancer clinics (35.5%) remain important for biopsy, excision, and Mohs surgery.
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
North America leads global cSCC market share at an estimated 44.8%, supported by high disease incidence and established treatment infrastructure, while Asia-Pacific is identified as the fastest-growing region.

Competitive Landscape
• Regeneron Pharmaceuticals
• Merck & Co.
• Eli Lilly
• Johnson & Johnson
• Replimune
Regeneron Pharmaceuticals: Regeneron holds the strongest branded pharmaceutical position in the cSCC market through Libtayo (cemiplimab), which now covers locally advanced, metastatic, and high-risk adjuvant disease, and the company is also pursuing an intralesional cemiplimab program for early-stage cSCC.
Merck & Co.: Merck competes through Keytruda (pembrolizumab) in advanced and locally advanced cSCC, though its position in the adjuvant setting is weaker after KEYNOTE-630 was discontinued for not meeting its recurrence-free-survival threshold.
Replimune: Replimune is developing RP1, an oncolytic immunotherapy being studied specifically in transplant recipients with advanced cutaneous malignancies, including cSCC, through its ARTACUS program, targeting a population historically excluded from checkpoint-inhibitor studies.
Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/cutaneous-squamous-cell-carcinoma-market?akash

Regional Analysis
Europe is estimated to account for 26.1% of the global cutaneous squamous cell carcinoma market share in 2025, equivalent to around USD 522 million, making it the second-largest regional market covered in the report. Within Europe, Germany represents the largest individual country market at an estimated 5.0% of global revenue, followed by the United Kingdom at 4.4% and France at 3.9%, with Italy and Spain contributing smaller shares.
The region's treatment revenue is supported by broad dermatology access, established surgical infrastructure, and expanding uptake of systemic immunotherapy, with the European Medicines Agency's current Libtayo authorization now including adjuvant treatment for cSCC. From to the DataM Intelligence report, North America is the dominant regional market, holding an estimated 44.8% share, while Asia-Pacific is identified as the fastest-growing region, with a modeled CAGR of 9.2% through 2035.

Conclusion
The cutaneous squamous cell carcinoma market growth is expected to experience significant growth over the forecast period, expanding at a steady pace. While Mohs surgery and surgical excision remain the largest component of the market due to the sheer volume of localized cases, immunotherapy is reshaping the market's value structure, particularly following the approval of adjuvant cemiplimab for high-risk resected disease. Ongoing trials targeting early-stage intralesional treatment and immunosuppressed or transplant populations point to further diversification in how cSCC is managed over the next decade.
Surgery, Mohs procedures, and immunotherapy together define a competitive landscape led by Regeneron and Merck, with emerging interest from Johnson & Johnson, Eli Lilly, and Replimune in underserved patient segments. Regionally, North America retains the largest share of the market, Europe holds a substantial secondary position anchored by Germany, the UK, and France, and Asia-Pacific is set to grow the fastest as treatment access expands across the region. Taken together, these dynamics point to a market that is growing steadily in volume while becoming increasingly weighted toward higher-value systemic treatment.
Unlock Complete Market Intelligence with the Full Report: https://www.datamintelligence.com/buy-now-page?report=cutaneous-squamous-cell-carcinoma-market?akash

Industry Related Reports:
Tumor Microenvironment Targeted Oncology Therapies Market Growth
The global Tumor Microenvironment Targeted Oncology Therapies Market reached USD 1.92 billion in 2025 and is expected to reach USD 5.11 billion by 2033, growing at a CAGR of 13% during 2026-2033. Rising demand for next-generation immunotherapies and targeted cancer treatments is driving growth in this market.
Get More Insights: https://www.datamintelligence.com/research-report/tumor-microenvironment-targeted-oncology-therapies-market?akash

Prostate Cancer Drugs Market Trends
The global Prostate Cancer Drugs Market reached USD 13.22 billion in 2024 and is expected to reach USD 28.10 billion by 2033, growing at a CAGR of 8.1% during 2025-2033. Market growth is supported by increasing prostate cancer incidence, expanding use of targeted therapies, and continued advances in oncology drug development.
Get More Insights: https://www.datamintelligence.com/research-report/prostate-cancer-drugs-market?akash

Get More Japan Market Insights: https://www.datamintelligence.com/jp-market-research-report?akash

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.